摘要:
A dosage form comprises (1) a solid amorphous dispersion comprising a cholesterol ester transfer protein inhibitor and an acidic concentration-enhancing polymer and (2) an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.
摘要:
Forming amorphous atorvastatin comprises the steps of dissolving atorvastatin in a hydroxylic solvent, followed by rapidly evaporating the solvent. In another aspect, a composition comprises particles of amorphous atorvastatin and a core.
摘要:
There is disclosed a method of separating enantiomers of 4-(3',4'-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone comprising contacting the same with a homogeneous or nonhomogeneous liquid mixture of solvent and water, the mixture containing substantially pure and unsupported gamma-cyclodextrin or its derivatives. Also disclosed are methods of further enantiomerically enriching solid mixtures obtained from the enantiomer separation method and further extracting one enantiomer by solvent extraction of the solid mixtures obtained.